Some Hits and Some Misses: Analysing Kemin Industries vs Controller of Patents

/ By / Others, Patent

Image from here Imagine that your client has come up with an invention (a process) that enables animals on your farm to absorb more energy than is usual from their feed/diet. It coincidently might also increase the economic value of the animals, mostly poultry and swine, after consuming the enhanced feed. Would this be a method of treatment for animals that is barred by Section 3(i)?  Madras High Court delivered a judgement answering this specific question and more. The Court […]

Some Hits and Some Misses: Analysing Kemin Industries vs Controller of Patents Read More »

[Sponsored] From Law to Leadership: How the MIPLC LL.M. Transforms Careers in IP and Competition Law

/ By / Sponsored

Admissions for LL.M. in Intellectual Property and Competition Law at Munich Intellectual Property Law Center (MIPLC) are now open! Take a look below at their sponsored post to know more about the benefits of the programme. From Law to Leadership: How the MIPLC LL.M. Transforms Careers in IP and Competition Law If you’re reading this, chances are you’re already intrigued by the world of intellectual property, data, and competition law, and the ever-shifting terrain of the digital economy. Maybe you’re

[Sponsored] From Law to Leadership: How the MIPLC LL.M. Transforms Careers in IP and Competition Law Read More »

[Sponsored] Call for Applications: Advanced International Certificate Course on IP Asset Management (April 20)

/ By / Sponsored

WIPO Academy, the Korean Intellectual Property Office (KIPO), the Korea Invention Promotion Association (KIPA), and the Korea Advanced Institute of Science and Technology (KAIST) are inviting applications for the annual Advanced International Certificate Course (AICC) on Intellectual Property Asset Management for Business Success. The course is fully sponsored for selected candidates and the last date to apply for the Course is April 20 (~11:59 p.m. Korea Time). For more details, please read their call for applications below. Register Now: Advanced

[Sponsored] Call for Applications: Advanced International Certificate Course on IP Asset Management (April 20) Read More »

Image with SpicyIP logo and the words "Weekly Review"

SpicyIP Weekly Review (March 31 – April 6)

/ By / Copyright, Drug Regulation, Others, Patent, Trademark

Keep up with the ever changing world of IP with SpicyIP’s Weekly Review! Beginning April with a three-part post exposing the alarming lack of transparency surrounding public funds spent on indigenously developed COVID-19 vaccines, a two part post on the latest Kunal Kamra controversy and its copyright implications, and the difficulty in getting cancer related information in India. This and much more in this week’s SpicyIP Weekly Review. Anything we are missing out on? Drop a comment below to let

SpicyIP Weekly Review (March 31 – April 6) Read More »

[Part II] Fair Dealing or Foul Play? The Latest Kunal Kamra Controversy

/ By / Copyright

Continuing the discussion on the Kunal Kamra controversy, Anjali dives deep into the implications on free speech that this incident can have. In Part I, she discussed the fair dealing exception with respect to the controversy. Anjali Tripathi is a fourth-year law student at JGLS with an interest in IP rights, access to education, and the creative arts. Her previous post can be accessed here. Fair Dealing or Foul Play? The Latest Kunal Kamra Controversy By Anjali Tripathi In Part I

[Part II] Fair Dealing or Foul Play? The Latest Kunal Kamra Controversy Read More »

[Part I] Fair Dealing or Foul Play? The Latest Kunal Kamra Controversy

/ By / Copyright

Amidst protests from political parties over his recent stand up set “Naya Bharat” and the looming threat of prosecution over jokes cracked on Maharashtra Deputy CM, Kunal Kamra faces new challenges in the form of copyright strikes on YouTube over this standup special. In this two part post, Anjali explains the controversy and discusses whether Kamra’s “jokes” can be protected under fair dealing exception, in Part I. In Part II, she dives into the free speech implications of this case,

[Part I] Fair Dealing or Foul Play? The Latest Kunal Kamra Controversy Read More »

The Great Indian Cancer Information Treasure Hunt

/ By / Drug Regulation, Others, Patent

[This post has been co-authored by Swaraj and Sabeeh. Long post ahead] Cancer incidences continue to increase in India, with over 1.46 million estimated new cases diagnosed annually as of 2022 and predicted to rise to 1.57 million cases by 2025 (More on these numbers later!). The continuous interaction of public health priorities with IP laws have been mainstream discussion for a long time now. To what extent exactly do IP laws create, shape, or impact the political economy of

The Great Indian Cancer Information Treasure Hunt Read More »

[Part III] Should Delhi High Court be Inviting Pharmaceutical Companies for its Official Event to Mark World IP Day?

/ By / Others

After two hard-hitting posts (Part I and Part II) on transparency surrounding public money in COVID-19 vaccines, Prashant Reddy wraps up this three part saga with a curious incident. Here, he writes on the DHC’s move to invite Bharath Biotech’s executive as a guest to its official event marking World IP Day, 2023. In this post, Prashant engages with pressing questions like- should active litigants be invited as guests to the events hosted by High Courts? And, wouldn’t such a

[Part III] Should Delhi High Court be Inviting Pharmaceutical Companies for its Official Event to Mark World IP Day? Read More »

[Part II] Public Money, Private Patents? Unravelling India’s Opacity over its COVID Vaccines

/ By / Others, Patent

Continuing the discussion on opacity behind the public money invested in development of COVID-19 vaccines, Prashant Reddy T, in Part II of his post, recounts his struggle with the government, including his eventual litigation to access essential public documents related to government funding in the vaccines. Please Note: This part includes some sections from Part I and was previously published in Newslaundry here. Prashant is one of our most prolific bloggers (his posts can be accessed here). He is also the co-author of three

[Part II] Public Money, Private Patents? Unravelling India’s Opacity over its COVID Vaccines Read More »

[Part I] India’s Hypocrisy over the TRIPs Waiver During the Pandemic

/ By / Patent

In a series of three hard-hitting posts, Prashant Reddy T exposes the alarming lack of transparency surrounding public funds spent on indigenously developed COVID-19 vaccines. He details his ordeal in attempting to obtain crucial information from the government and raises pressing concerns about the absence of accountability in public spending. Part I highlights the government’s hypocrisy during the pandemic—seeking a global TRIPS waiver before the WTO while simultaneously allowing the patenting of publicly funded COVID-related inventions in India and overseas.

[Part I] India’s Hypocrisy over the TRIPs Waiver During the Pandemic Read More »

Scroll to Top